Frontlight ResearchEarly access
CompletedPhase 3
Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)
Key facts
- Who runs it
- Evopoint Biosciences Inc.
- Where
- Baltimore, Buffalo, Charlotte, Cleveland, Denver, Hartford, Knoxville, Miami, Springfield, and Tampa, United StatesSee the 10 sitesAlso in 3 other countries, 25 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 450 people enrolled
- Started
- 31 Jul 2022
- Ended
- 29 Sept 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Combination of Imipenem/Cilastatin and XNW4107
- Imipenem/Cilastatin/Relebactam
- Record updated
- 6 November 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Has HABP or VABP as defined below and requires treatment with IV antibiotic therapy. Fulfills clinical criteria, with onset of criteria occurring after more than 48 hours of hospitalization or within 7 days after discharge from a hospital (for HABP); or at least 48 hours after mechanical ventilation (for VABP)
- Fulfills clinical criteria with symptoms or signs of cough, expectorated sputum production, dyspnea, worsening oxygenation, increase in respiratory secretions, fever/ hypothermia
- Fulfills laboratory test criteria with Leukocytosis/ Leukocytosis/ increase in immature neutrophils
- Fulfill radiograph criteria with presence of new or progressive infiltrate(s) suggestive of bacterial pneumonia in X-ray/ Chest CT
- Female subjects of childbearing potential, who are willing to birth control during the study and for at least 30 days following the last dose of study medication. Male subjects with female sexual partners of childbearing potential are eligible for inclusion if they agree to use birth control for 90 days following the last dose of study medication. Male subjects must agree not to donate sperm
Who cannot take part
- Have received effective antibacterial drug therapy for the index infection of HABP/VABP for more than 24 hours during the previous 72 hours
- Documented or severe hypersensitivity or previous severe adverse drug reaction, especially to any beta-lactam antibiotics, or any of the excipients used in the study drug formulations
- History of a seizure disorder requiring ongoing treatment with anti-convulsive therapy or prior treatment with anti-convulsive therapy within the last 3 years
- Patient is receiving hemodialysis or peritoneal dialysis
- Have known or suspected community-acquired bacterial pneumonia, atypical pneumonia, viral pneumonia including Coronavirus disease, or chemical pneumonia
- Have HABP/VABP caused by an obstructive process, including lung cancer or other known obstruction
- Have central nervous system infection
- Documented presence of immunodeficiency or an immunocompromised condition
- History of active liver disease or cirrhosis
- eGFR <15 mL/min/1.73㎡
- Anticipated to be treated with any of Valproic acid or divalproex sodium, concomitant systemic Gram-negative antibacterial agents, or concomitant systemic antifungal or antiviral therapy for the index infection of HABP/VABP
- Patients with 1 or more of laboratory abnormalities in baseline specimens
- Gram stain from a respiratory sample shows only Gram-positive cocci
- Life expectancy is <3 days
- Patients in refractory septic shock
- APACHE II score of >30
- A female who is pregnant or breastfeeding or has a positive pregnancy test at Screening
Where in United States
Also in 3 other countries, 25 sites
- University of Maryland Medical CenterBaltimore, United States
- VA medical centerBuffalo, United States
- Carolinas Medical CenterCharlotte, United States
- University Hospitals Cleveland Medical Center*Cleveland, United States
- Denver Health and Hospital AuthorityDenver, United States
- Hartford HospitalHartford, United States
- The University of Tennessee Medical CenterKnoxville, United States
- Jackson Memorial Hospital (JMH) - Ryder Trauma CenterMiami, United States
- Cox HealthSpringfield, United States
- USF-TGHTampa, United States
About the trial
What the trial wants to find out
This study aims to compare treatment with Imipenem/Cilastatin-XNW4107 (IMI-XNW4107) with imipenem/cilastatin/relebactam (IMI/REL) in participants with hospital-acquired or ventilator-associated bacterial pneumonia (HABP or VAPB, respectively). The primary hypothesis is that IMI-XNW4107 is non-inferior to IMI/REL in all-cause mortality.
The 2 groups in the trial
- Imipenem/Cilastatin/XNW4107Treatment being tested
Imipenem/Cilastatin 500mg/500mg in combination with XNW4107 250mg, Q6h (0.5h Infusion)
Treatment: Combination of Imipenem/Cilastatin and XNW4107
- Imipenem/Cilastatin/RelebactamExisting treatment, for comparison
Imipenem/Cilastatin/Relebactam 1.25g Q6h (0.5h Infusion)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-Blind, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Imipenem/Cilastatin/Relebactam in Adults With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia (EudraCT no. 2022-000081-18) (EUCTR no. 2022-501952-27-00) (IND no. 146614)
- Record updated
- 6 November 2025